For the first time in Brazil, a patient received cancer treatment with CART-Cell cells outside of a scientific study. The procedure was performed on January 9, at the Complexo Hospitalar de Niterói (CHN), in Rio de Janeiro. The 74-year-old man is due to be discharged from the hospital on February 6 after a month of observation.

CART-Cell was approved by the National Health Surveillance Agency (Anvisa) in 2022. Until then, it was only available for academic research. It emerged as a hope for patients with some types of cancer, such as lymphomas, acute lymphocytic leukemia and multiple myeloma, who did not obtain the expected results in two other previous therapies.

“CART-Cell represents a possibility of cure for patients who have already tried at least two other therapies without results”, says hematologist Luciana Conti, responsible for the procedure in Brazil.

Civil engineer Carlos Alberto Wagner, 74, was the first Brazilian to undergo therapy. The procedure was performed in a private hospital, with all treatment paid for by the health plan. He has diffuse large B-cell non-Hodgkin’s lymphoma and had already undergone three different types of treatment – ​​two chemotherapy and one radiotherapy –, all without the expected result.

“We tried three treatments. When he found out that the disease was not over, he was a little angry”, says Wagner’s wife, Aldelúcia Porto Maciel Wagner.

Advertising by Metrópoles 1 partner
Advertising by Metrópoles 2 partner
Advertising by Metrópoles 3 partner
Advertising by Metrópoles 4 partner

0

CART-Cell

CART-Cell cell therapy – Chimeric Antigen Receptor T-Cell Therapy – is a procedure capable of combating hematological cancers using the patient’s own defense cells (T lymphocytes), modified in the laboratory and reinserted by infusion.

“By being genetically modified, T lymphocytes become more active against tumors in the blood”, explains the hematologist.

Carlos Alberto’s cells were collected on November 11 and sent to a laboratory in New Jersey, in the United States, where genetic modification of the cells was carried out to potentiate them. The genetic material returned to Brazil on December 27th and the patient was hospitalized a week later for preparations for the infusion.

The engineer underwent three chemotherapy sessions to immunosuppress his defense system and allow the enhanced cells to be able to replicate without difficulty, increasing the chances of success.

The doctor explains that the cells receive a kind of “potency” in the laboratory, with a target (the anti CD19) to attack the malignant cells in the body. This makes them able to visualize and destroy the cancer again.

After the genetic modification of the T lymphocyte carried out in the laboratory, the material is transformed into an injectable medication, applied in a single dose to the patient through infusion, as occurs in blood transfusions.

encouraging results

According to Luciana, Carlos Alberto has already passed the most critical phase after the infusion and may be discharged soon. The expectation is that this will occur on February 6, after completing 28 days of the procedure.

“The patient needs to be closely monitored for at least 28 days. It is a very critical moment, because like any medicine, there are adverse effects. One of them, the most serious, is what we call cytokine release syndrome, which is like an inflammatory storm. Therefore, there is little care at this stage”, reinforces the doctor.

Aldelúcia says that her husband reacted very well to the procedure and the family is hopeful that he will finally be able to heal. “Of course, we need to walk further in the coming days to understand better, but we are hopeful,” she says.

Get news from metropolises on your Telegram and stay on top of everything! Just access the channel: https://t.me/metropolesurgente.

California18

Welcome to California18, your number one source for Breaking News from the World. We’re dedicated to giving you the very best of News.

Leave a Reply